Morgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40
Morgan Stanley analyst Thibault Boutherin downgrades Novo Nordisk (NYSE:NVO) from Equal-Weight to Underweight and maintains the price target from $40 to $40.
A big bank's expert said Novo Nordisk looks less attractive than before, even though they kept the same price target. Watch to see if other experts agree, because that might mean the company faces new challenges ahead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.